Delivery Order 36F79724D0101-36C24924N0625
Award Date
8/22/24
Potential Completion Date
9/26/24
Potential Value
Not listed
Federal Agency
Veterans Integrated Service Network 9
Awardee
Bristol-Myers Squibb Company
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Lawrenceville, Lawrence Township, NJ 08648, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Department of Veterans Affairs (VA) Veterans Health Administration to Bristol-Myers Squibb Company, a global biopharmaceutical company. The award, valued at $314,322.29, is a delivery order against Bristol-Myers Squibb's Federal Supply Schedule (FSS) contract with the VA (ID: 36F79724D0101). The FSS contract has a ceiling value of $12,278,876,570.00 and runs through April 30, 2029. Under this contract, Bristol-Myers Squibb is providing the CAR T cell...
This federal contract award is for the delivery of ABECMA (idecabtagene vicleucel) injections to the U.S. Department of Veterans Affairs (VA) healthcare system. The prime contractor is Bristol-Myers Squibb Company, a global biopharmaceutical firm that specializes in oncology and immunotherapy products. This delivery order, valued at $314,322.29, is placed against Bristol-Myers Squibb's existing Federal Supply Schedule (FSS) contract with the VA (ID: 36F79724D0101), which has a ceiling value of...
This federal contract award is for the delivery of BREYANZI, a chimeric antigen receptor (CAR) T cell immunotherapy product, to the Department of Veterans Affairs (VA) for the treatment of a veteran patient. The contract was awarded to Bristol-Myers Squibb Company, a large pharmaceutical manufacturer, and has a ceiling value of $335,042.65. The contract is a firm fixed price delivery order under Bristol-Myers Squibb's existing Federal Supply Schedule contract (ID: 36F79724D0101) with the VA,...
This federal contract award was issued by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 9 (VISN 9) to Bristol-Myers Squibb Company, a global biopharmaceutical company, for the delivery of BREYANZI, a chimeric antigen receptor (CAR) T-cell therapy used to treat non-Hodgkin lymphoma. The $310,953.67 firm fixed-price delivery order has an ultimate completion date of August 30, 2024. This award is a call against Bristol-Myers Squibb's existing Federal Supply Schedule...
This is a federal delivery order contract awarded by the U.S. Department of Veterans Affairs (VA) to Bristol-Myers Squibb Company, a large pharmaceutical manufacturer. The $335,042.65 firm fixed price contract is for the delivery of the BREYANZI chimeric antigen receptor (CAR) T cell therapy for transplant treatment. The contract is part of Bristol-Myers Squibb's larger $12.28 billion Federal Supply Schedule contract with the VA, which provides a wide range of drugs, pharmaceuticals, and...
The Department of Veterans Affairs Veterans Health Administration awarded a delivery order to Bristol-Myers Squibb Company under the company's Pharmaceuticals and Drugs Federal Supply Schedule contract. The $314,322.29 firm fixed price order is for the provision of IDECABTAGENE VICLEUCEL INJ,SUSP (ABECMA), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T immunotherapy. The delivery order has a performance period through April 12, 2024 and the work will take place...
This is a delivery order awarded by the U.S. Department of Veterans Affairs (VA) Veterans Integrated Service Network (VISN) 9 to Bristol-Myers Squibb Company for the supply of ABECMA, an injectable suspension used in the treatment of certain types of transplant procedures. The $338,932.84 firm fixed price contract does not carry a set-aside designation, reflecting Bristol-Myers Squibb's status as a large pharmaceutical manufacturer. The delivery order is placed against Bristol-Myers Squibb's...
The Department of Veterans Affairs Veterans Health Administration awarded a delivery order contract to Bristol-Myers Squibb Company, doing business as Bristol-Myers Squibb, a global biopharmaceutical company. The $314,322.29 firm fixed price contract is for the provision of IDECABTAGENE VICLEUCEL, with a period of performance from March 20, 2024 to April 30, 2024. This delivery order is part of Bristol-Myers Squibb's broader Federal Supply Schedule contract with the Department of Veterans...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 19 (VA-VHA) awarded a $320,422.11 delivery order contract to Bristol-Myers Squibb Company Bristol Myers Squibb Division for the pharmaceutical ABECMA. Bristol-Myers Squibb Company is the parent company of the prime contractor. The contract utilizes the Pharmaceuticals and Drugs Federal Supply Schedule 61-IB master contract. Performance will take place in Lawrenceville, New Jersey over the period...
Bristol-Myers Squibb Company was awarded a delivery order against its Pharmaceuticals and Drugs Federal Supply Schedule contract to provide $313,394.97 worth of BREYANZI to the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 19. BREYANZI is a chimeric antigen receptor T cell immunotherapy used to treat certain types of non-Hodgkin lymphoma. The delivery order was issued on a firm fixed price basis and has a period of performance through October...